North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.510

-3.8%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nathan L. who wrote (70)	11/8/1996 11:22:00 AM
From: andy harrison	of 82

If Sturza is what you imply and his credibility wanes; would it not be advantagous to invest in NVX??? The "REAL" analysts have written time and time again that NVX will be a dominant player in the pediatric and adult vaccine market. The DTaP products are just the tip of the NVX iceberg. They are working on a series of Menigitis vaccines including A,B, & C and have a blockbuster vaccine in trial....Group B Strep (GBS). Target market in the US alone is 100,000,000 to 150,000,000 women. It is staggering!!! Sturza is stuck in a position that if he backs down on his negative position the stock will fly. He has to continue to put the heat on. He has created a situation where probably less than 1% of the entire shares outstanding are in the hands of individual investors. Remember that Phil Frost, Biochem, and the insiders own 62% of the stock and institutions own between 35-37% of the stock. Andy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next